Xeris Biopharma (NASDAQ:XERS) Director Sells $60,020.36 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director James Aloysius Brady sold 10,834 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the transaction, the director directly owned 89,166 shares in the company, valued at approximately $493,979.64. This represents a 10.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Xeris Biopharma Stock Performance

NASDAQ XERS traded up $0.05 on Thursday, hitting $6.09. 365,669 shares of the company traded hands, compared to its average volume of 2,009,358. The business’s 50 day moving average price is $6.39 and its 200-day moving average price is $7.31. Xeris Biopharma Holdings, Inc. has a 52-week low of $3.81 and a 52-week high of $10.08. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -608.29 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on XERS. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Barclays initiated coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Xeris Biopharma has an average rating of “Moderate Buy” and an average target price of $10.80.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XERS. Cetera Investment Advisers increased its position in Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after purchasing an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Xeris Biopharma by 7.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock worth $150,000 after acquiring an additional 2,264 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Xeris Biopharma by 6.5% during the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after purchasing an additional 2,351 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Xeris Biopharma by 17.7% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock worth $126,000 after purchasing an additional 2,420 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.